187 related articles for article (PubMed ID: 34880297)
21. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
Guo J; Cui Z; Zheng Y; Li X; Chen Y
Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
[TBL] [Abstract][Full Text] [Related]
23. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
[TBL] [Abstract][Full Text] [Related]
24. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.
Farrell RA; Antony D; Wall GR; Clark DA; Fisniku L; Swanton J; Khaleeli Z; Schmierer K; Miller DH; Giovannoni G
Neurology; 2009 Jul; 73(1):32-8. PubMed ID: 19458321
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus infection and risk of lymphoma: immunoblot analysis of antibody responses against EBV-related proteins in a large series of lymphoma subjects and matched controls.
de Sanjosé S; Bosch R; Schouten T; Verkuijlen S; Nieters A; Foretova L; Maynadié M; Cocco PL; Staines A; Becker N; Brennan P; Benavente Y; Boffetta P; Meijer CJ; Middeldorp JM
Int J Cancer; 2007 Oct; 121(8):1806-12. PubMed ID: 17557295
[TBL] [Abstract][Full Text] [Related]
26. Molecular diversity of IgG responses to Epstein-Barr virus proteins in asymptomatic Epstein-Barr virus carriers.
Goswami R; Shair KHY; Gershburg E
J Gen Virol; 2017 Sep; 98(9):2343-2350. PubMed ID: 28795661
[TBL] [Abstract][Full Text] [Related]
27. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study.
Li Z; Xia Y; Feng LN; Chen JR; Li HM; Cui J; Cai QQ; Sim KS; Nairismägi ML; Laurensia Y; Meah WY; Liu WS; Guo YM; Chen LZ; Feng QS; Pang CP; Chen LJ; Chew SH; Ebstein RP; Foo JN; Liu J; Ha J; Khoo LP; Chin ST; Zeng YX; Aung T; Chowbay B; Diong CP; Zhang F; Liu YH; Tang T; Tao M; Quek R; Mohamad F; Tan SY; Teh BT; Ng SB; Chng WJ; Ong CK; Okada Y; Raychaudhuri S; Lim ST; Tan W; Peng RJ; Khor CC; Bei JX
Lancet Oncol; 2016 Sep; 17(9):1240-7. PubMed ID: 27470079
[TBL] [Abstract][Full Text] [Related]
28. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
Front Immunol; 2018; 9():932. PubMed ID: 29765376
[TBL] [Abstract][Full Text] [Related]
29. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy.
Wang ZY; Liu QF; Wang H; Jin J; Wang WH; Wang SL; Song YW; Liu YP; Fang H; Ren H; Wu RY; Chen B; Zhang XM; Lu NN; Zhou LQ; Li YX
Blood; 2012 Sep; 120(10):2003-10. PubMed ID: 22826562
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr virus BART9 miRNA modulates LMP1 levels and affects growth rate of nasal NK T cell lymphomas.
Ramakrishnan R; Donahue H; Garcia D; Tan J; Shimizu N; Rice AP; Ling PD
PLoS One; 2011; 6(11):e27271. PubMed ID: 22102884
[TBL] [Abstract][Full Text] [Related]
31. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations.
Lin GW; Xu C; Chen K; Huang HQ; Chen J; Song B; Chan JKC; Li W; Liu W; Shih LY; Chuang WY; Kim WS; Tan W; Peng RJ; Laurensia Y; Cheah DMZ; Huang D; Cheng CL; Su YJ; Tan SY; Ng SB; Tang TPL; Han K; Wang VY; Jia WH; Pei Z; Li YJ; Gao S; Shi Y; Hu Z; Zhang F; Zhang B; Zeng YX; Shen H; He L; Ong CK; Lim ST; Chanock S; Kwong YL; Lin D; Rothman N; Khor CC; Lan Q; Bei JX;
Lancet Oncol; 2020 Feb; 21(2):306-316. PubMed ID: 31879220
[TBL] [Abstract][Full Text] [Related]
32. Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol.
Wang XX; Li PF; Bai B; Gao Y; Rong QX; Cai QQ; Lin SX; Zhang YJ; Li ZM; Jiang WQ; Huang HQ
Leuk Lymphoma; 2019 Aug; 60(8):1917-1925. PubMed ID: 30646796
[TBL] [Abstract][Full Text] [Related]
33. Increased antibody levels to stage-specific Epstein-Barr virus antigens in systemic autoimmune diseases reveal a common pathology.
Sternbæk L; Draborg AH; Østerlund MT; Iversen LV; Troelsen L; Theander E; Nielsen CT; Jacobsen S; Houen G
Scand J Clin Lab Invest; 2019; 79(1-2):7-16. PubMed ID: 30727744
[TBL] [Abstract][Full Text] [Related]
34. Detection of IgG directed against a recombinant form of Epstein-Barr virus BALF0/1 protein in patients with nasopharyngeal carcinoma.
Shao Z; Borde C; Marchand CH; Lemaire SD; Busson P; Gozlan JM; Escargueil A; Maréchal V
Protein Expr Purif; 2019 Oct; 162():44-50. PubMed ID: 31145974
[TBL] [Abstract][Full Text] [Related]
35. Schizophrenia is Associated With an Aberrant Immune Response to Epstein-Barr Virus.
Dickerson F; Jones-Brando L; Ford G; Genovese G; Stallings C; Origoni A; O'Dushlaine C; Katsafanas E; Sweeney K; Khushalani S; Yolken R
Schizophr Bull; 2019 Sep; 45(5):1112-1119. PubMed ID: 30462333
[TBL] [Abstract][Full Text] [Related]
36. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
[TBL] [Abstract][Full Text] [Related]
37. High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies.
Chen CJ; Lin KH; Lin SC; Tsai WC; Yen JH; Chang SJ; Lu SN; Liu HW
J Rheumatol; 2005 Jan; 32(1):44-7. PubMed ID: 15630723
[TBL] [Abstract][Full Text] [Related]
38. Antibody titers against EBNA1 and EBNA2 in relation to Hodgkin lymphoma and history of infectious mononucleosis.
Mueller NE; Lennette ET; Dupnik K; Birmann BM
Int J Cancer; 2012 Jun; 130(12):2886-91. PubMed ID: 21805472
[TBL] [Abstract][Full Text] [Related]
39. Differences in the Epstein-Barr Virus gp350 IgA Antibody Response Are Associated With Increased Risk for Coinfection With a Second Strain of Epstein-Barr Virus.
Smith NA; Baresel PC; Jackson CL; Ogolla S; Toko EN; Heit S; Piriou E; Sumba OP; Middeldorp JM; Colborn KL; Rochford R
J Infect Dis; 2019 Feb; 219(6):955-963. PubMed ID: 30312417
[TBL] [Abstract][Full Text] [Related]
40. Evaluation the Architect EBV VCA IgM, VCA IgG, and EBNA-1 IgG chemiluminescent immunoassays to assess EBV serostatus prior transplantation.
Maylin S; Feghoul L; Salmona M; Herda A; Mercier-Delarue S; Simon F; Legoff J
J Med Virol; 2017 Nov; 89(11):2003-2010. PubMed ID: 28661055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
